Π£ΡΠ°ΡΡΠΈΠ΅ Π°Π΄Π°ΠΏΡΠΎΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² RIL ΠΈ TRIP6 Π² ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ° ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ
Π‘Π»ΠΎΠ²Π° ΠΎΡΠΎΠ±ΠΎΠΉ ΠΏΡΠΈΠ·Π½Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Ρ ΠΎΡΠ΅Π»Π° Π±Ρ Π²ΡΡΠΊΠ°Π·Π°ΡΡ Π² Π°Π΄ΡΠ΅Ρ ΠΠ½Π½Ρ Π‘Π°Π±Π»ΠΈΠ½ΠΎΠΉ, ΠΊΠΎΡΠΎΡΠ°Ρ Π½Π°ΡΡΠΈΠ»Π° ΠΌΠ΅Π½Ρ ΠΌΠ½ΠΎΠ³ΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌ ΠΈ Π±Π΅Π· ΡΡΠ΅ΠΉ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΈ ΡΡΠ° ΡΠ°Π±ΠΎΡΠ° Π½Π΅ Π±ΡΠ»Π° Π±Ρ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΡΠ°ΠΊ ΡΠΊΠΎΡΠΎ. Π― Π±Π»Π°Π³ΠΎΠ΄Π°ΡΡ Π ΠΎΠΌΠ°Π½Π° ΠΠΎΠ½Π΄ΡΠ°ΡΠΎΠ²Π° Π·Π° ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π·Π°ΠΌΠ΅ΡΠ°Π½ΠΈΡ ΠΈ ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠΈΠ΅ Π΄ΠΈΡΠΊΡΡΡΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΠ»ΡΠ³Ρ Π Π°Π·ΠΎΡΠ΅Π½ΠΎΠ²Ρ ΠΈ ΠΠ»Π΅ΠΊΡΠ°Π½Π΄ΡΠ° ΠΠ°ΡΠΏΠ°ΡΡΡΠ½Π° Π·Π° ΠΏΠΎΠΌΠΎΡΡ Π² ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΠΊ Π·Π°ΡΠΈΡΠ΅. Π― Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½Π° ΡΠ»Π΅Π½Π°ΠΌ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΠΉ Π. Π. Π€ΡΠΎΠ»ΠΎΠ²ΠΎΠΉ, Π… Π§ΠΈΡΠ°ΡΡ Π΅ΡΡ >
- Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- ΠΡΠ΄Π΅ΡΠΆΠΊΠ°
- ΠΠΈΡΠ΅ΡΠ°ΡΡΡΠ°
- ΠΡΡΠ³ΠΈΠ΅ ΡΠ°Π±ΠΎΡΡ
- ΠΠΎΠΌΠΎΡΡ Π² Π½Π°ΠΏΠΈΡΠ°Π½ΠΈΠΈ
Π‘ΠΎΠ΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅
- Π‘ΠΏΠΈΡΠΎΠΊ ΡΠΎΠΊΡΠ°ΡΠ΅Π½ΠΈΠΉ
- I. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- 1. 1. ΠΠ΄Π°ΠΏΡΠΎΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ
- 1. 1. 1. ΠΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ LIM-Π΄ΠΎΠΌΠ΅Π½ΠΎΠ²
- 1. 1. 2. Π₯Π°ΡΠ°ΠΊΡΠ΅ΡΠΈΡΡΠΈΠΊΠ° PDZ-Π΄ΠΎΠΌΠ΅Π½ΠΎΠ²
- 1. 2. ΠΠ΅Π½ TRIP
- 1. 3. ΠΠ΅Π½ RIL
- 1. 3. 1. RIL — ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»Ρ ΡΠ΅ΠΌΠ΅ΠΉΡΡΠ²Π° Π±Π΅Π»ΠΊΠΎΠ² ALP/Enigma
- 1. 3. 2. ΠΡΠΎΠΈΡΡ ΠΎΠΆΠ΄Π΅Π½ΠΈΠ΅ ΠΈ ΡΠ²ΠΎΠ»ΡΡΠΈΠΎΠ½Π½Π°Ρ ΠΊΠΎΠ½ΡΠ΅ΡΠ²Π°ΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ΅ΠΌΠ΅ΠΉΡΡΠ²Π° ALP/Enigma
- 1. 3. 3. ΠΠ΅Π½ΠΎΠΌΠ½Π°Ρ ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π³Π΅Π½Π° RIL ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 1. 3. 4. ΠΠ»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠ΅ ΡΡΠ°Π½ΡΠΊΡΠΈΠΏΡΡ Π³Π΅Π½Π° RIL ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 1. 3. 5. ΠΠ²ΠΎΠ»ΡΡΠΈΠΎΠ½Π½Π°Ρ ΠΊΠΎΠ½ΡΠ΅ΡΠ²Π°ΡΠΈΠ²Π½ΠΎΡΡΡ RIL
- 1. 3. 6. ΠΠ½Π°Π»ΠΈΠ· ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ RIL ΠΈ Π΄ΡΡΠ³ΠΈΡ ΡΠ»Π΅Π½ΠΎΠ² ΡΠ΅ΠΌΠ΅ΠΉΡΡΠ²Π° ALP/Enigma Π² ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ ΡΠΊΠ°Π½ΡΡ
- 1. 3. 7. Π Π΅ΠΏΠ΅ΡΡΡΠ°Ρ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΉ Π±Π΅Π»ΠΊΠ° RIL
- 1. 1. ΠΠ΄Π°ΠΏΡΠΎΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ
- 1. 3. 8. Π ΠΎΠ»Ρ RIL Π² ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΠΈ ΡΡΡΡΠΊΡΡΡΡ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΡΡ ΡΡΡΠ΅ΡΡ-ΡΠΈΠ±ΡΠΈΠ»Π»
- 1. 3. 9. Π’ΡΠ°Π½ΡΠΏΠΎΡΡΠ½Π°Ρ ΡΡΠ½ΠΊΡΠΈΡ RIL
- 1. 3. 10. ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠ΅ ΡΡΠ°ΡΡΠΈΠ΅ RIL Π² Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ
- 1. 3. 11. ΠΠ°Π½Π½ΡΠ΅ ΠΎ Π΄ΠΈΡΡΠ΅ΡΠ΅Π½ΡΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ RIL, ΠΏΠΎΠ»ΡΡΠ΅Π½Π½ΡΠ΅ Ρ ΠΈΡΠΏΠΎΠ»ΡΠ·ΠΎΠ²Π°Π½ΠΈΠ΅ΠΌ ΠΌΠΈΠΊΡΠΎΠΏΠ°Π½Π΅Π»Π΅ΠΉ ΠΎΠ»ΠΈΠ³ΠΎΠ½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄ΠΎΠ²
- 1. 4. ΠΠ΅Π½ΡΠΈΠ²ΠΈΡΡΡΠ½Π°Ρ ΡΠΈΡΡΠ΅ΠΌΠ° ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ
- 1. 5. Π ΠΠ-ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠ΅Π½ΡΠΈΡ
- II. 1. Π Π°Π±ΠΎΡΠ° Ρ ΠΊΡΠ»ΡΡΡΡΠ°ΠΌΠΈ ΡΡΠΊΠ°ΡΠΈΠΎΡΠΈΡΠ΅ΡΠΊΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ
- II. 2. Π Π°Π±ΠΎΡΠ° Ρ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ ΠΈ ΠΊΠ»ΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅
- 11. 2. 1. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ E. col
- 11. 2. 2. Π’ΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΡ Ρ ΠΈΠΌΠΈΡΠ΅ΡΠΊΠΈ ΠΊΠΎΠΌΠΏΠ΅ΡΠ΅Π½ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ E. col
- 11. 2. 3. ΠΡΠ΅ΠΏΠ°ΡΠ°ΡΠΈΠ²Π½ΠΎΠ΅ ΠΈ Π°Π½Π°Π»ΠΈΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΏΠ»Π°Π·ΠΌΠΈΠ΄Π½ΠΎΠΉ ΠΠΠ
- 11. 2. 4. ΠΠ±ΡΠ°Π±ΠΎΡΠΊΠ° ΠΠΠ ΡΠ½Π΄ΠΎΠ½ΡΠΊΠ»Π΅Π°Π·Π°ΠΌΠΈ ΡΠ΅ΡΡΡΠΈΠΊΡΠΈΠΈ
- 11. 2. 5. Π€ΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ ΠΈΠ·Π²Π»Π΅ΡΠ΅Π½ΠΈΠ΅ ΠΠΠ ΠΈΠ· Π°Π³Π°ΡΠΎΠ·Π½ΡΡ Π³Π΅Π»Π΅ΠΉ
- 11. 2. 9. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΈΠΉ Π΄Π»Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π ΠΠ-ΡΠΏΠΈΠ»Π΅ΠΊ Π΄Π»Ρ Π ΠΠ-ΠΈΠΈΡΠ΅ΡΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ
- 11. 2. 10. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠ΅ΠΏΠΎΡΡΠ΅ΡΠ½ΡΡ ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΈΠΉ
- 11. 3. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΈ Π°Π½Π°Π»ΠΈΠ· Π ΠΠ
- 11. 3. 1. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ Π ΠΠ, ΡΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΈ ΠΏΠ΅ΡΠ΅Π½ΠΎΡ Π½Π° ΠΌΠ΅ΠΌΠ±ΡΠ°Π½Ρ
- 11. 3. 2. ΠΠΎΠ·Π΅ΡΠ½-Π±Π»ΠΎΡ Π°Π½Π°Π»ΠΈΠ·
- 11. 3. 3. ΠΠ’-ΠΠ¦Π
- 11. 3. 4. ΠΡΠ΄Π΅Π»Π΅Π½ΠΈΠ΅ ΠΈ Π°Π½Π°Π»ΠΈΠ· ΠΌΠ ΠΠ, ΡΠ²ΡΠ·Π°Π½Π½ΠΎΠΉ ΠΏΠΎΠ»ΠΈΡΠΎΠΌΠ°ΠΌΠΈ
- 11. 4. ΠΠ΅ΡΠΎΠ΄Ρ Π²ΡΠ΄Π΅Π»Π΅Π½ΠΈΡ ΠΈ Π°Π½Π°Π»ΠΈΠ·Π° Π±Π΅Π»ΠΊΠΎΠ²
- 11. 4. 1. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ ΡΠΎΡΠ°Π»ΡΠ½ΡΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ Π»ΠΈΠ·Π°ΡΠΎΠ²
- 11. 4. 2. ΠΠΎΠ»ΡΡΠ΅Π½ΠΈΠ΅ Triton Π₯-100-ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠΉ ΠΈ Π½Π΅ΡΠ°ΡΡΠ²ΠΎΡΠΈΠΌΠΎΠΉ ΡΡΠ°ΠΊΡΠΈΠΉ
- 11. 4. 3. Π€ΡΠ°ΠΊΡΠΈΠΎΠ½ΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ Π±Π΅Π»ΠΊΠΎΠ², ΠΏΠ΅ΡΠ΅Π½ΠΎΡ Π½Π° ΠΌΠ΅ΠΌΠ±ΡΠ°Π½Ρ ΠΈ ΠΈΠΌΠΌΡΠ½ΠΎΠ΄Π΅ΡΠ΅ΠΊΡΠΈΡ
- 11. 4. 4. ΠΠΌΠΌΡΠ½ΠΎΠΏΡΠ΅ΡΠΈΠΏΠΈΡΠ°ΡΠΈΡ
- 11. 4. 5. ΠΠΌΠΌΡΠ½ΠΎΡΠ»ΡΠΎΡΠ΅ΡΡΠ΅Π½ΡΠΈΡ
- 11. 4. 6. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΡ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ ΠΈ Π½Π΅ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠΈΠ·ΠΎΠ²Π°Π½Π½ΠΎΠ³ΠΎ Π°ΠΊΡΠΈΠ½Π° Ρ ΠΏΠΎΠΌΠΎΡΡΡ ΠΊΠΎΠ½ΡΠΎΠΊΠ°Π»ΡΠ½ΠΎΠΉ ΠΌΠΈΠΊΡΠΎΡΠΊΠΎΠΏΠΈΠΈ
- 11. 4. 6. ΠΠΎΠ»ΠΎΡΠΈΠΌΠ΅ΡΡΠΈΡΠ΅ΡΠΊΠΎΠ΅ ΠΈΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Ρ-Π³Π°Π»Π°ΠΊΡΠΎΠ·ΠΈΠ΄Π°Π·Ρ (ONPG-ΠΎΠΊΡΠ°ΡΠΈΠ²Π°Π½ΠΈΠ΅)
- 11. 4. 7. ΠΠ·ΠΌΠ΅ΡΠ΅Π½ΠΈΠ΅ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ Π»ΡΡΠΈΡΠ΅ΡΠ°Π·Ρ
- 11. 4. 8. ΠΡΠ΅Π½ΠΊΠ° Π²ΡΠ΅ΠΌΠ΅Π½ΠΈ ΠΏΠΎΠ»ΡΠΆΠΈΠ·Π½ΠΈ Π±Π΅Π»ΠΊΠ°
- III. 1. ΠΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΡ Π½Π΅ΠΊΠΎΡΠΎΡΡΡ ΠΌΠ΅ΡΠΎΠ΄ΠΎΠ²
- 111. 2. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΠΎΠ³ΠΎ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ TR1P6 ΠΈ RIL Π½Π° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ
- 111. 2. 1. Π’Π΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΠ΅ ΠΊΠΎΠ½ΡΡΡΡΠΊΡΠΈΠΉ Π΄Π»Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ shPHK, ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΡΡ Π³Π΅Π½Π°ΠΌ TRIP6 ΠΈ RIL
- 111. 2. 2. ΠΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½Π° TRIP6 ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ
- 111. 2. 3. ΠΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΠ΅ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½Π° RIL Π²Π»ΠΈΡΠ΅Ρ Π½Π° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ
- 111. 2. 4. ΠΠ»ΠΈΡΠ½ΠΈΠ΅ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½ΠΈΡ ΡΡΠΎΠ²Π½Π΅ΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ TRIP6 ΠΈ RIL Π½Π° ΡΠΊΠΎΡΠΎΡΡΡ ΠΌΠΈΠ³ΡΠ°ΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ
- 111. 2. 5. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ TRIP6 ΠΈ RIL ΠΈ ΡΠΊΠΎΡΠΎΡΡΡ ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ
- 111. 2. 6. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ TRIP6 ΠΈ RIL ΠΏΠΎ-ΡΠ°Π·Π½ΠΎΠΌΡ Π²Π»ΠΈΡΠ΅Ρ Π½Π° ΡΠΏΠΎΡΠΎΠ±Π½ΠΎΡΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊ ΡΠΎΡΡΡ Π² ΡΡΠ»ΠΎΠ²ΠΈΡΡ Π°Π½ΠΎΠΉΠΊΠΈΡΠ°
- 111. 2. 7. ΠΠΈΠΏΠ΅ΡΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ RIL ΡΡΠΈΠ»ΠΈΠ²Π°Π΅Ρ Π°Π΄Π³Π΅Π·ΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ
- 111. 2. 8. ΠΠΎΠ·ΠΌΠΎΠΆΠ½ΡΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΡ ΡΡΡΠ΅ΠΊΡΠΎΠ², Π½Π°Π±Π»ΡΠ΄Π°Π΅ΠΌΡΡ ΠΏΡΠΈ ΠΏΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ TRIP
- 111. 3. ΠΠΎΠ·ΠΌΠΎΠΆΠ½Π°Ρ ΡΠΎΠ»Ρ RIL ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 111. 3. 1. ΠΠ½Π°Π»ΠΈΠ· ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ ΠΌΠ ΠΠ RIL Π² ΠΎΠΏΡΡ ΠΎΠ»ΡΡ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 111. 3. 2. ΠΠΊΡΠΏΡΠ΅ΡΡΠΈΡ RIL Π² ΠΊΡΠ»ΡΡΡΡΠ°Ρ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°
- 111. 3. 3. Π‘ΡΠ°ΡΡΡ RIL ΠΎΠ±ΡΠ°ΡΠ½ΠΎ ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠ΅ΠΉ ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠ°ΡΠΊΠ΅ΡΠ° Π-ΠΊΠ°Π΄Π³Π΅ΡΠΈΠ½Π° Π² ΠΊΡΠ»ΡΡΡΡΠ°Ρ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠ°ΠΊΠ° ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 111. 3. 4. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ RIL ΠΈ Π-ΠΊΠ°Π΄Π³Π΅ΡΠΈΠ½Π° ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ
- 111. 4. Π ΠΎΠ»Ρ Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΡ
ΠΈΠ·ΠΎΡΠΎΡΠΌ RIL Π² ΡΠ΅ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ°
- 111. 4. 1. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ RIL Ρ Π°-Π°ΠΊΡΠΈΠ½ΠΈΠ½ΠΎΠΌ
- 111. 4. 2. ΠΠ»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠ΅ Π²Π°ΡΠΈΠ°Π½ΡΡ RIL ΠΈΠΌΠ΅ΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ Π² ΠΊΠ»Π΅ΡΠΊΠ΅
- 111. 4. 3. ΠΠ·ΠΎΡΠΎΡΠΌΡ RIL ΠΌΠ΅Π½ΡΡΡ ΡΠ°ΡΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ Π°-Π°ΠΊΡΠΈΠ½ΠΈΠ½Π°-1 ΠΌΠ΅ΠΆΠ΄Ρ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅Ρ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠΌ ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ΠΌ ΠΈ ΡΠΈΡΠΎΠ·ΠΎΠ»Π΅ΠΌ
- 111. 4. 4. RIL ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΡΠ΅ΠΏΠ΅Π½Ρ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ½Π° Π·Π° ΡΡΠ΅Ρ ΡΠ²ΠΎΠ΅Π³ΠΎ LIM Π΄ΠΎΠΌΠ΅Π½Π°
- 111. 4. 5. LIM Π΄ΠΎΠΌΠ΅Π½ RIL ΠΈΠ½Π³ΠΈΠ±ΠΈΡΡΠ΅Ρ ΡΠ°Π·Π±ΠΎΡΠΊΡ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΡΡ Π²ΠΎΠ»ΠΎΠΊΠΎΠ½
- III. 5. ΠΠ°ΡΠ±ΠΎΠΊΡΠΈΡΠ΅ΡΠΌΠΈΠ½Π°Π»ΡΠ½ΡΠΉ ΠΏΠ΅ΠΏΡΠΈΠ΄ Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΡ
ΡΠΎΡΠΌ RIL ΡΠ²Π»ΡΠ΅ΡΡΡ ΡΠΈΠ³Π½Π°Π»ΠΎΠΌ ΠΏΡΠΎΡΠ΅Π°ΡΠΎΠΌΠ½ΠΎΠΉ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ
- 111. 5. 1. ΠΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΡΠΎΡΠΊΠΎΠΆΠΈΠ²ΡΡΠΈΡ ΡΠΎΡΠΌ RIL
- 111. 5. 2. ΠΠ»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠΉ Π‘-ΠΊΠΎΠ½ΡΠ΅Π²ΠΎΠΉ ΠΏΠ΅ΠΏΡΠΈΠ΄ RIL Π΄Π΅ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·ΠΈΡΡΠ΅Ρ Π³Π΅ΡΠ΅ΡΠΎΠ»ΠΎΠ³ΠΈΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ
- 111. 5. 3. ΠΠ»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΡΠΉ Π‘-ΠΊΠΎΠ½ΡΠ΅Π²ΠΎΠΉ ΠΏΠ΅ΠΏΡΠΈΠ΄ RIL ΡΠΎΠ΄Π΅ΡΠΆΠΈΡ PEST-ΠΌΠΎΡΠΈΠ² — ΡΠΈΠ³Π½Π°Π» ΠΏΡΠΎΡΠ΅Π°ΡΠΎΠΌΠ½ΠΎΠΉ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ
Π£ΡΠ°ΡΡΠΈΠ΅ Π°Π΄Π°ΠΏΡΠΎΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² RIL ΠΈ TRIP6 Π² ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ° ΠΈ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ (ΡΠ΅ΡΠ΅ΡΠ°Ρ, ΠΊΡΡΡΠΎΠ²Π°Ρ, Π΄ΠΈΠΏΠ»ΠΎΠΌ, ΠΊΠΎΠ½ΡΡΠΎΠ»ΡΠ½Π°Ρ)
ΠΠ΅Π΄Π°Π²Π½Π΅Π΅ Π·Π°Π²Π΅ΡΡΠ΅Π½ΠΈΠ΅ ΠΏΡΠΎΠ΅ΠΊΡΠ° «Π³Π΅Π½ΠΎΠΌ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ°» ΠΏΠ°ΡΠ°Π»Π»Π΅Π»ΡΠ½ΠΎ Ρ ΠΎΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ΠΌ ΠΏΠΎΠ»Π½ΠΎΠΉ ΠΏΠ΅ΡΠ²ΠΈΡΠ½ΠΎΠΉ ΡΡΡΡΠΊΡΡΡΡ Π³Π΅Π½ΠΎΠΌΠΎΠ² ΠΌΠ½ΠΎΠ³ΠΈΡ Π΄ΡΡΠ³ΠΈΡ ΠΎΡΠ³Π°Π½ΠΈΠ·ΠΌΠΎΠ², Π° ΡΠ°ΠΊΠΆΠ΅ Π½Π°ΠΊΠΎΠΏΠ»Π΅Π½ΠΈΠ΅ Π±ΠΎΠ»ΡΡΠΎΠ³ΠΎ ΠΌΠ°ΡΡΠΈΠ²Π° Π΄Π°Π½Π½ΡΡ ΠΎΠ± ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡΡΠ΅ΠΌΡΡ ΠΏΠΎΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΡΡ ΡΡΠ°Π²ΡΡ ΠΏΠ΅ΡΠ΅Π΄ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°ΡΠ΅Π»ΡΠΌΠΈ ΠΏΡΠΈΠ½ΡΠΈΠΏΠΈΠ°Π»ΡΠ½ΠΎ Π½ΠΎΠ²ΡΠ΅ Π·Π°Π΄Π°ΡΠΈ ΠΏΠΎ ΠΎΠ±ΠΎΠ±ΡΠ΅Π½ΠΈΡ, ΠΊΠ»Π°ΡΡΠΈΡΠΈΠΊΠ°ΡΠΈΠΈ ΠΈ ΡΡΡΡΠΊΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΡΠΎΠΉ ΠΈΠ½ΡΠΎΡΠΌΠ°ΡΠΈΠΈ. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΉ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ Π³Π΅Π½ΠΎΠ², ΠΏΠΎΠΈΡΠΊ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΡΠ²ΡΠ·Π΅ΠΉ ΠΌΠ΅ΠΆΠ΄Ρ Π½ΠΈΠΌΠΈ, ΠΎΠ±ΡΠ΅Π΄ΠΈΠ½Π΅Π½ΠΈΠ΅ ΠΈΡ Π² ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ΅ΠΏΠΎΡΠΊΠΈ, Π° Π·Π°ΡΠ΅ΠΌ ΠΈ Π² ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΡΠ΅ΡΠΈΠΏΡΠΈΠΎΡΠΈΡΠ΅ΡΠ½ΠΎΠ΅ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΡΡ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ Π³Π΅Π½Π΅ΡΠΈΠΊΠΈ. ΠΠ»ΡΡΠ΅Π²ΡΡ ΡΠΎΠ»Ρ Π² ΠΈΠ½ΡΠ΅Π³ΡΠ°ΡΠΈΠΈ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ ΠΊΠ°ΡΠΊΠ°Π΄ΠΎΠ² ΠΈ ΡΠΎΠ½ΠΊΠΎΠΉ ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ ΠΈΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΉ ΠΈΠ³ΡΠ°ΡΡ LIM-Π΄ΠΎΠΌΠ΅Π½Π½ΡΠ΅ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅Ρ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΠ΅ Π°Π΄Π°ΠΏΡΠΎΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ, ΠΏΡΠ΅Π΄ΡΡΠ°Π²ΠΈΡΠ΅Π»ΡΠΌΠΈ ΠΊΠΎΡΠΎΡΡΡ ΡΠ²Π»ΡΡΡΡΡ ΠΏΡΠΎΠ΄ΡΠΊΡΡ Π³Π΅Π½ΠΎΠ² RIL ΠΈ TRIP6.
Π ΡΠ²Π΅ΡΠ΅ ΠΌΠ½ΠΎΠ³ΠΎΡΠΈΡΠ»Π΅Π½Π½ΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΉ ΠΏΠΎΡΠ»Π΅Π΄Π½ΠΈΡ Π»Π΅Ρ Π½Π΅ΠΊΠΎΠ³Π΄Π° ΠΏΡΠΈΠ½ΡΡΠ°Ρ ΡΠΎΡΠΊΠ° Π·ΡΠ΅Π½ΠΈΡ, ΡΡΠΎ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΡΠΉ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅Ρ — ΠΏΡΠΎΡΡΠΎ ΡΡΠ°ΡΠΈΡΠ΅ΡΠΊΠ°Ρ ΡΡΡΡΠΊΡΡΡΠ°, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠ°Ρ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠ°Π½ΠΈΠ΅ ΡΠΎΡΠΌΡ ΠΊΠ»Π΅ΡΠΎΠΊ, Π²ΡΠ³Π»ΡΠ΄ΠΈΡ ΡΡΠ΅Π·ΠΌΠ΅ΡΠ½ΡΠΌ ΡΠΏΡΠΎΡΠ΅Π½ΠΈΠ΅ΠΌ. Π‘ΠΎΡΡΠΎΡΠ½ΠΈΠ΅ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ° ΠΌΠΎΠ΄ΡΠ»ΠΈΡΡΠ΅Ρ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΠΌΠ½ΠΎΠ³ΠΈΡ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ ΠΊΠ°ΡΠΊΠ°Π΄ΠΎΠ²Π΅Π³ΠΎ ΠΈΠ½ΡΠ°ΠΊΡΠ½ΠΎΡΡΡ — Π½Π΅ΠΎΠ±Ρ ΠΎΠ΄ΠΈΠΌΠΎΠ΅ ΡΡΠ»ΠΎΠ²ΠΈΠ΅ Π²Π½ΡΡΡΠΈΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠ³ΠΎ ΡΡΠ°Π½ΡΠΏΠΎΡΡΠ° ΠΎΡΠ³Π°Π½Π΅Π»Π». Π Π΅ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ° ΠΈΠ³ΡΠ°Π΅Ρ ΠΎΡΠ½ΠΎΠ²Π½ΡΡ ΡΠΎΠ»Ρ Π² ΠΏΡΠΎΡΠ΅ΡΡΠ°Ρ Π°Π΄Π³Π΅Π·ΠΈΠΈ ΠΈ ΠΌΠΈΠ³ΡΠ°ΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΡΠΈ ΠΈΡ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΡΠ°Π½ΡΡΠΎΡΠΌΠ°ΡΠΈΠΈ. Π ΡΠ²ΡΠ·ΠΈ Ρ ΡΡΠΈΠΌ Π²ΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΠΊΠΎΠ½ΠΊΡΠ΅ΡΠ½ΡΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ ΡΠΎΡΡΠΎΡΠ½ΠΈΡ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ°, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΏΠΎΠΈΡΠΊ ΠΈ Π²ΡΠ΅ΡΡΠΎΡΠΎΠ½Π½Π΅Π΅ ΠΈΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π±Π΅Π»ΠΊΠΎΠ², Π²ΠΎΠ²Π»Π΅ΡΠ΅Π½Π½ΡΡ Π² ΡΡΠΈ ΠΏΡΠΎΡΠ΅ΡΡΡ, ΡΠ²Π»ΡΠ΅ΡΡΡ ΠΎΠ΄Π½ΠΈΠΌ ΠΈΠ· ΠΏΡΠΈΠΎΡΠΈΡΠ΅ΡΠ½ΡΡ Π½Π°ΠΏΡΠ°Π²Π»Π΅Π½ΠΈΠΉ ΡΠΎΠ²ΡΠ΅ΠΌΠ΅Π½Π½ΠΎΠΉ ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ ΠΈ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅Ρ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² RIL ΠΈ TRIP6 ΠΌΠΎΠΆΠ΅Ρ ΠΏΡΠΎΠ»ΠΈΡΡ ΡΠ²Π΅Ρ Π½Π° ΠΌΠ½ΠΎΠ³ΠΈΠ΅ Π°ΡΠΏΠ΅ΠΊΡΡ ΠΊΠ»Π΅ΡΠΎΡΠ½ΠΎΠΉ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠΉ ΠΏΡΠΎΠ³ΡΠ΅ΡΡΠΈΠΈ, ΠΎΡΠΊΡΡΠ²Π°Π΅Ρ ΡΠΈΡΠΎΠΊΠΈΠ΅ ΠΏΠ΅ΡΡΠΏΠ΅ΠΊΡΠΈΠ²Ρ Π΄Π»Ρ Π΄Π΅ΡΠ°Π»ΡΠ½ΠΎΠ³ΠΎ ΡΠ΅ΠΊΠΎΠ½ΡΡΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΠΈΡ ΡΡΠ°ΡΡΠΈΡ Π² ΡΠ΅ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ° Π² Π½ΠΎΡΠΌΠ΅ ΠΈ ΠΏΠ°ΡΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈ Π·Π°ΠΊΠ»Π°Π΄ΡΠ²Π°Π΅Ρ ΠΎΡΠ½ΠΎΠ²Ρ Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ Π² Π±ΡΠ΄ΡΡΠ΅ΠΌ Π½ΠΎΠ²ΡΡ ΠΏΠΎΠ΄Ρ ΠΎΠ΄ΠΎΠ² ΠΊ Π΄ΠΈΠ°Π³Π½ΠΎΡΡΠΈΠΊΠ΅ ΠΈ Π»Π΅ΡΠ΅Π½ΠΈΡ ΡΠ°ΠΊΠ°.
ΠΡΠ½ΠΎΠ²Π½ΠΎΠΉ ΡΠ΅Π»ΡΡ Π΄Π°Π½Π½ΠΎΠΉ ΡΠ°Π±ΠΎΡΡ ΡΠ²ΠΈΠ»ΠΎΡΡ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅Ρ-Π°ΡΡΠΎΡΠΈΠΈΡΠΎΠ²Π°Π½Π½ΡΡ LIM-Π΄ΠΎΠΌΠ΅Π½Π½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² TRIP6 ΠΈ RIL, ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΡ Π½Π° ΡΠ΅ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΡ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ°, Π½Π° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡ ΠΈ ΡΠΈΠ·ΠΈΠΎΠ»ΠΎΠ³ΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΈΡ Π²ΠΎΠ·ΠΌΠΎΠΆΠ½ΠΎΠ΅ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΠΈΠ½Π²Π°Π·ΠΈΠ²Π½ΡΠ΅ ΡΠ²ΠΎΠΉΡΡΠ²Π° ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ.
Π Ρ ΠΎΠ΄Π΅ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΡ Π±ΡΠ»ΠΈ ΠΏΠΎΡΡΠ°Π²Π»Π΅Π½Ρ ΡΠ»Π΅Π΄ΡΡΡΠΈΠ΅ Π·Π°Π΄Π°ΡΠΈ:
1. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ Π²Π»ΠΈΡΠ½ΠΈΡ ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ TRIP6 Π½Π° ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠ΅ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠ΅ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠ½ΠΈΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ.
2. ΠΠ·ΡΡΠ΅Π½ΠΈΠ΅ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΡ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΡ ΠΎΡΠΎΠ±Π΅Π½Π½ΠΎΡΡΠ΅ΠΉ ΠΊΠ»Π΅ΡΠΎΠΊ Π»ΠΈΠ½ΠΈΠΉ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ Ρ ΠΈΠ·ΠΌΠ΅Π½Π΅Π½Π½ΡΠΌ ΡΡΠΎΠ²Π½Π΅ΠΌ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ RIL.
3. ΠΠ½Π°Π»ΠΈΠ· ΡΡΠΎΠ²Π½Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ RIL Π² ΠΎΠΏΡΡ ΠΎΠ»ΡΡ ΡΠ°Π·Π»ΠΈΡΠ½ΠΎΠ³ΠΎ Π³ΠΈΡΡΠΎΠ³Π΅Π½Π΅Π·Π°, Π² ΡΠ°ΡΡΠ½ΠΎΡΡΠΈ ΠΏΡΠΈ ΡΠ°ΠΊΠ΅ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ.
4. ΠΡΡΠ²Π»Π΅Π½ΠΈΠ΅ ΡΠΎΠ»ΠΈ Π΄ΠΎΠΌΠ΅Π½ΠΎΠ² Π±Π΅Π»ΠΊΠ° RIL ΠΏΡΠΈ Π΅Π³ΠΎ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΈ Ρ Π°Π»ΡΡΠ°-Π°ΠΊΡΠΈΠ½ΠΈΠ½ΠΎΠΌ, ΠΈ ΠΈΡ Π²Π»ΠΈΡΠ½ΠΈΠ΅ Π½Π° ΡΠΎΡΡΠΎΡΠ½ΠΈΠ΅ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ°.
5. ΠΠΏΡΠ΅Π΄Π΅Π»Π΅Π½ΠΈΠ΅ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΠΎΠ³ΠΎ ΠΌΠΎΡΠΈΠ²Π° Π±Π΅Π»ΠΊΠ° RIL, Π²Π»ΠΈΡΡΡΠ΅Π³ΠΎ Π½Π° ΡΡΠ°Π±ΠΈΠ»ΡΠ½ΠΎΡΡΡ Π±Π΅Π»ΠΊΠ° RIL, ΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠ΅ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠ° Π΅Π³ΠΎ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ.
Π ΠΌΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΡΡΠΈ ΡΠ°Π±ΠΎΡΡ Π±ΡΠ»ΠΈ ΠΏΠΎΡΡΠ°Π²Π»Π΅Π½Ρ Π·Π°Π΄Π°ΡΠΈ ΠΏΠΎ ΠΎΠΏΡΠΈΠΌΠΈΠ·Π°ΡΠΈΠΈ ΡΠΏΠ°ΠΊΠΎΠ²ΠΊΠΈ Π»Π΅Π½ΡΠΈΠ²ΠΈΡΡΡΠ½ΡΡ ΡΠ°ΡΡΠΈΡ Π΄Π»Ρ ΠΏΠΎΠ²ΡΡΠ΅Π½ΠΈΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ ΡΡΠ°Π½ΡΠ΄ΡΠΊΡΠΈΠΈ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΎΠ½Π½ΡΡ ΠΊΠ°ΡΡΠ΅Ρ Π² ΠΊΠ»Π΅ΡΠΊΠΈ-ΠΌΠΈΡΠ΅Π½ΠΈ ΠΈ ΠΏΠΎ ΡΠΎΠ²Π΅ΡΡΠ΅Π½ΡΡΡΠ²ΠΎΠ²Π°Π½ΠΈΡ ΡΡΡΡΠΊΡΡΡΡ Π ΠΠ-ΡΠΏΠΈΠ»ΡΠΊΠΈ Π΄Π»Ρ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ Π ΠΠ-ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ Π² ΡΠ°ΠΌΠΊΠ°Ρ Π»Π΅Π½ΡΠΈΠ²ΠΈΡΡΡΠ½ΠΎΠΉ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ.
I. ΠΠ±Π·ΠΎΡ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ 1.1. ΠΠ΄Π°ΠΏΡΠΎΡΠ½ΡΠ΅ Π±Π΅Π»ΠΊΠΈ.
ΠΡΠ½ΠΎΠ²Π½Π°Ρ ΠΎΡΠ»ΠΈΡΠΈΡΠ΅Π»ΡΠ½Π°Ρ ΡΠ΅ΡΡΠ° Π°Π΄Π°ΠΏΡΠΎΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² — Π½Π°Π»ΠΈΡΠΈΠ΅ Π½Π΅ΡΠΊΠΎΠ»ΡΠΊΠΈΡ Π΄ΠΎΠΌΠ΅Π½ΠΎΠ², ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠΈΡ Π±Π΅Π»ΠΎΠΊ-Π±Π΅Π»ΠΊΠΎΠ²ΡΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ. ΠΠ΅Π»ΠΊΠΈ ΡΡΠΎΠ³ΠΎ ΠΊΠ»Π°ΡΡΠ° ΡΠ»ΡΠΆΠ°Ρ ΠΎΡΠ½ΠΎΠ²ΠΎΠΉ Π΄Π»Ρ ΠΎΠ±ΡΠ°Π·ΠΎΠ²Π°Π½ΠΈΡ ΠΊΡΡΠΏΠ½ΡΡ ΡΠΈΠ³Π½Π°Π»ΡΠ½ΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ², ΠΎΡΠ²Π΅ΡΠ°Ρ Π·Π° ΠΏΡΠ°Π²ΠΈΠ»ΡΠ½ΠΎΠ΅ ΠΏΡΠΎΠ²Π΅Π΄Π΅Π½ΠΈΠ΅ ΡΠΈΠ³Π½Π°Π»Π°. ΠΠ½ΠΈ Π΄ΠΈΠΊΡΡΡΡ ΡΠΏΠ΅ΡΠΈΡΠΈΡΠ½ΠΎΡΡΡ ΠΌΠ΅ΠΆΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΡΡ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠΉ, Π²Π½ΡΡΡΠΈΠΊΠ»Π΅ΡΠΎΡΠ½ΡΡ Π»ΠΎΠΊΠ°Π»ΠΈΠ·Π°ΡΠΈΡ ΠΎΡΠ΄Π΅Π»ΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ² ΠΈ ΡΠ΅Π»ΡΡ ΠΊΠΎΠΌΠΏΠ»Π΅ΠΊΡΠΎΠ² ΠΈ ΠΌΠΎΠ³ΡΡ ΠΌΠΎΠ΄ΡΠ»ΠΈΡΠΎΠ²Π°ΡΡ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΡ ΡΠ²ΠΎΠΈΡ Π±Π΅Π»ΠΊΠΎΠ²-ΠΏΠ°ΡΡΠ½Π΅ΡΠΎΠ² [1].
ΠΡΡΡΡΡΡΠ²ΠΈΠ΅ Ρ TRIP6 ΠΈ RIL ΡΠΎΠ±ΡΡΠ²Π΅Π½Π½ΠΎΠΉ ΡΠ΅ΡΠΌΠ΅Π½ΡΠ°ΡΠΈΠ²Π½ΠΎΠΉ Π°ΠΊΡΠΈΠ²Π½ΠΎΡΡΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ Π½Π°Π»ΠΈΡΠΈΠ΅ PDZ (Ρ RIL) ΠΈ LIM-Π΄ΠΎΠΌΠ΅Π½ΠΎΠ² (Ρ TRIP6 ΠΈ RIL) — ΠΌΠΎΡΠΈΠ²ΠΎΠ², ΠΎΡΠ²Π΅ΡΡΡΠ²Π΅Π½Π½ΡΡ Π·Π° Π±Π΅Π»ΠΎΠΊ-Π±Π΅Π»ΠΊΠΎΠ²ΡΠ΅ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΡ, — ΠΏΠΎΠ·Π²ΠΎΠ»ΡΡΡ ΠΎΡΠ½Π΅ΡΡΠΈ ΠΈΡ ΠΊ ΠΊΠ»Π°ΡΡΡ Π°Π΄Π°ΠΏΡΠΎΡΠ½ΡΡ Π±Π΅Π»ΠΊΠΎΠ². Π Π°ΡΡΠΌΠΎΡΡΠΈΠΌ ΡΡΡΡΠΊΡΡΡΡ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΈ ΡΡΠΈΡ Π΄Π²ΡΡ Π΄ΠΎΠΌΠ΅Π½ΠΎΠ² Π±ΠΎΠ»Π΅Π΅ ΠΏΠΎΠ΄ΡΠΎΠ±Π½ΠΎ.
ΠΡΠ²ΠΎΠ΄Ρ.
1. ΠΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½Π° TRIP6 Π² Π»ΠΈΠ½ΠΈΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΡΠ΅ΠΎΡΠ³Π°Π½ΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ° ΠΈ Π΄ΡΡΠ³ΠΈΠΌ ΠΌΠΎΡΡΠΎΠ»ΠΎΠ³ΠΈΡΠ΅ΡΠΊΠΈΠΌ ΠΈ ΡΡΠ½ΠΊΡΠΈΠΎΠ½Π°Π»ΡΠ½ΡΠΌ ΡΠ΄Π²ΠΈΠ³Π°ΠΌ, Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΠΌ Π΄Π»Ρ ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎ-ΠΌΠ΅Π·Π΅Π½Ρ ΠΈΠΌΠ°Π»ΡΠ½ΠΎΠΉ ΡΡΠ°Π½Π·ΠΈΡΠΈΠΈ.
2. ΠΠΎΠ²ΡΡΠ΅Π½Π½Π°Ρ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ RIL Π² Π»ΠΈΠ½ΠΈΡΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠ°ΡΡΠΈΠ½ΠΎΠΌ ΠΈΠ½Π΄ΡΡΠΈΡΡΠ΅Ρ ΠΌΠ΅Π·Π΅Π½Ρ ΠΈΠΌΠ½ΡΠΉ ΡΠ΅Π½ΠΎΡΠΈΠΏ, ΠΏΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΈ ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΠΊΠΎΡΠΎΡΡΡ ΠΈΡ ΠΌΠΈΠ³ΡΠ°ΡΠΈΠΈ. ΠΡΠΈ ΡΡΠΎΠΌ Π³ΠΈΠΏΠ΅ΡΡΠΊΡΠΏΡΠ΅ΡΡΠΈΡ RIL ΡΡΠΈΠ»ΠΈΠ²Π°Π΅Ρ Π°Π΄Π³Π΅Π·ΠΈΡ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΊΠ°ΠΊ ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ, ΡΠ°ΠΊ ΠΈ Π½Π΅ΡΠΏΠΈΡΠ΅Π»ΠΈΠ°Π»ΡΠ½ΠΎΠΉ ΠΏΡΠΈΡΠΎΠ΄Ρ. ΠΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΠ΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ RIL, Π½Π°ΠΎΠ±ΠΎΡΠΎΡ, ΠΏΡΠΈΠ²ΠΎΠ΄ΠΈΡ ΠΊ ΠΏΠΎΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΡΠΈΠ·Π½Π°ΠΊΠΎΠ², Ρ Π°ΡΠ°ΠΊΡΠ΅ΡΠ½ΡΡ Π΄Π»Ρ ΠΌΠ΅Π½Π΅Π΅ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΠΎΠ³ΠΎ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΠΎΠ³ΠΎ ΡΠ΅Π½ΠΎΡΠΈΠΏΠ°.
3. ΠΡΠΈ Π°Π½Π°Π»ΠΈΠ·Π΅ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ RIL Π² ΠΎΠ±ΡΠ°Π·ΡΠ°Ρ Π·Π»ΠΎΠΊΠ°ΡΠ΅ΡΡΠ²Π΅Π½Π½ΡΡ ΠΎΠΏΡΡ ΠΎΠ»Π΅ΠΉ ΠΌΠΎΠ»ΠΎΡΠ½ΠΎΠΉ ΠΆΠ΅Π»Π΅Π·Ρ ΡΠ΅Π»ΠΎΠ²Π΅ΠΊΠ° ΠΈ ΠΊΡΠ»ΡΡΡΡΠ°Ρ ΠΊΠ»Π΅ΡΠΎΠΊ ΡΠΎΠ³ΠΎ ΠΆΠ΅ ΠΏΡΠΎΠΈΡΡ ΠΎΠΆΠ΄Π΅Π½ΠΈΡ Π²ΡΡΠ²Π»Π΅Π½Π° ΡΠ΅Π½Π΄Π΅Π½ΡΠΈΡ ΠΊ ΠΏΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΡ RIL. ΠΡΠΈ ΡΡΠΎΠΌ Π²ΡΡΠΎΠΊΠΈΠΉ ΡΡΠΎΠ²Π΅Π½Ρ RIL ΠΊΠΎΡΡΠ΅Π»ΠΈΡΡΠ΅Ρ Ρ Π±ΠΎΠ»Π΅Π΅ Π°Π³ΡΠ΅ΡΡΠΈΠ²Π½ΡΠΌ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΠΌ ΡΠ΅Π½ΠΎΡΠΈΠΏΠΎΠΌ.
4. ΠΡΠΈ ΠΈΡΡΠ»Π΅Π΄ΠΎΠ²Π°Π½ΠΈΠΈ ΡΠΎΠ»ΠΈ RIL Π² ΡΠ΅Π³ΡΠ»ΡΡΠΈΠΈ Π΄ΠΈΠ½Π°ΠΌΠΈΠΊΠΈ Π°ΠΊΡΠΈΠ½ΠΎΠ²ΠΎΠ³ΠΎ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅ΡΠ° Π²Π½ΡΡΡΠΈ LIM-Π΄ΠΎΠΌΠ΅Π½Π° RIL Π²ΡΡΠ²Π»Π΅Π½ Π΄ΠΎΠΏΠΎΠ»Π½ΠΈΡΠ΅Π»ΡΠ½ΡΠΉ ΡΠ°ΠΉΡ, ΠΎΠ±Π΅ΡΠΏΠ΅ΡΠΈΠ²Π°ΡΡΠΈΠΉ Π²Π·Π°ΠΈΠΌΠΎΠ΄Π΅ΠΉΡΡΠ²ΠΈΠ΅ RIL Ρ Π°-Π°ΠΊΡΠΈΠ½ΠΈΠ½ΠΎΠΌ. ΠΠΎΠΊΠ°Π·Π°Π½ΠΎ, ΡΡΠΎ LIM Π΄ΠΎΠΌΠ΅Π½ RIL ΡΠ΅ΠΊΡΡΡΠΈΡΡΠ΅Ρ Π°-Π°ΠΊΡΠΈΠ½ΠΈΠ½ Π½Π° Π°ΠΊΡΠΈΠ½ΠΎΠ²ΡΠΉ ΡΠΈΡΠΎΡΠΊΠ΅Π»Π΅Ρ ΠΈ ΠΏΠΎΠ²ΡΡΠ°Π΅Ρ ΡΡΠ΅ΠΏΠ΅Π½Ρ ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠΈΠ·Π°ΡΠΈΠΈ Π°ΠΊΡΠΈΠ½Π° Π·Π° ΡΡΠ΅Ρ ΠΏΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΡ Π΅Π³ΠΎ Π΄Π΅ΠΏΠΎΠ»ΠΈΠΌΠ΅ΡΠΈΠ·Π°ΡΠΈΠΈ.
5. Π ΡΠΎΡΡΠ°Π²Π΅ Π°Π»ΡΡΠ΅ΡΠ½Π°ΡΠΈΠ²Π½ΠΎΠ³ΠΎ Π‘-ΠΊΠΎΠ½ΡΠ΅Π²ΠΎΠ³ΠΎ ΠΏΠ΅ΠΏΡΠΈΠ΄Π° Π΄Π²ΡΡ ΠΈΠ·ΠΎΡΠΎΡΠΌ RIL Π²ΡΡΠ²Π»Π΅Π½ PEST-ΠΌΠΎΡΠΈΠ², ΠΏΡΠΈΠ²ΠΎΠ΄ΡΡΠΈΠΉ ΠΊ Π΄Π΅ΡΡΠ°Π±ΠΈΠ»ΠΈΠ·Π°ΡΠΈΠΈ ΡΡΠΈΡ Π±Π΅Π»ΠΊΠΎΠ² ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²ΠΎΠΌ ΠΈΡ ΠΏΡΠΎΡΠ΅Π°ΡΠΎΠΌΠ½ΠΎΠΉ Π΄Π΅Π³ΡΠ°Π΄Π°ΡΠΈΠΈ.
6. Π ΠΌΠ΅ΡΠΎΠ΄ΠΈΡΠ΅ΡΠΊΠΎΠΉ ΡΠ°ΡΡΠΈ ΡΠ°Π±ΠΎΡΡ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ ΠΎΠΏΡΠΈΠΌΠ°Π»ΡΠ½ΠΎΠ΅ ΡΠΎΠΎΡΠ½ΠΎΡΠ΅Π½ΠΈΠ΅ ΠΊΠΎΠΌΠΏΠΎΠ½Π΅Π½ΡΠΎΠ² ΡΠΏΠ°ΠΊΠΎΠ²ΠΎΡΠ½ΠΎΠΉ ΡΠΌΠ΅ΡΠΈ, ΠΏΠΎΠ·Π²ΠΎΠ»ΠΈΠ²ΡΠ΅Π΅ ΡΠ²Π΅Π»ΠΈΡΠΈΡΡ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΡΠΉ ΡΠΈΡΡ ΠΏΠΎΠ»ΡΡΠ°Π΅ΠΌΡΡ Π²ΠΈΡΡΡΠ½ΡΡ ΠΏΡΠ΅ΠΏΠ°ΡΠ°ΡΠΎΠ² Π² 15−20 ΡΠ°Π·.
7. Π ΡΠ΅Π·ΡΠ»ΡΡΠ°ΡΠ΅ ΠΌΠ°ΡΡΡΠ°Π±Π½ΠΎΠ³ΠΎ ΡΠ΅ΡΡΠΈΡΠΎΠ²Π°Π½ΠΈΡ ΡΠ°Π·Π»ΠΈΡΠ½ΡΡ Π΄ΠΈΠ·Π°ΠΉΠ½ΠΎΠ² Π ΠΠ-ΡΠΏΠΈΠ»ΡΠΊΠΈ Π΄Π»Ρ ΠΎΡΡΡΠ΅ΡΡΠ²Π»Π΅Π½ΠΈΡ ΠΏΠΎΠ΄Π°Π²Π»Π΅Π½ΠΈΡ ΡΠΊΡΠΏΡΠ΅ΡΡΠΈΠΈ Π³Π΅Π½ΠΎΠ² ΠΏΠΎΡΡΠ΅Π΄ΡΡΠ²ΠΎΠΌ Π ΠΠ-ΠΈΠ½ΡΠ΅ΡΡΠ΅ΡΠ΅Π½ΡΠΈΠΈ ΡΡΡΠ°Π½ΠΎΠ²Π»Π΅Π½ΠΎ, ΡΡΠΎ Π½Π°ΠΈΠ±ΠΎΠ»Π΅Π΅ ΡΡΡΠ΅ΠΊΡΠΈΠ²Π½ΠΎΠΉ ΡΠ²Π»ΡΠ΅ΡΡΡ «ΠΊΠ»Π°ΡΡΠΈΡΠ΅ΡΠΊΠ°Ρ» ΡΡΡΡΠΊΡΡΡΠ° ΡΠΏΠΈΠ»ΡΠΊΠΈ Ρ 22-Π½ΡΠΊΠ»Π΅ΠΎΡΠΈΠ΄Π½ΡΠΌ ΡΡΠ΅Π±Π»Π΅ΠΌ.
ΠΠ»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΠΈ.
Π₯ΠΎΡΡ ΠΏΠΎΠ±Π»Π°Π³ΠΎΠ΄Π°ΡΠΈΡΡ ΡΠ²ΠΎΠ΅Π³ΠΎ Π½Π°ΡΡΠ½ΠΎΠ³ΠΎ ΡΡΠΊΠΎΠ²ΠΎΠ΄ΠΈΡΠ΅Π»Ρ ΠΠ»Π΅Π½Ρ ΠΠ²Π°Π½ΠΎΠ²Π½Ρ Π€ΡΠΎΠ»ΠΎΠ²Ρ Π·Π° ΠΏΡΠ΅Π΄ΠΎΡΡΠ°Π²Π»Π΅Π½ΠΈΠ΅ ΠΈΠ½ΡΠ΅ΡΠ΅ΡΠ½Π΅ΠΉΡΠ΅ΠΉ ΡΠ΅ΠΌΡ Π΄Π»Ρ ΡΠ°Π·ΡΠ°Π±ΠΎΡΠΊΠΈ.
Π‘Π²ΠΎΡ ΠΈΡΠΊΡΠ΅Π½Π½ΡΡ Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½ΠΎΡΡΡ Ρ ΠΎΡΡ Π²ΡΡΠ°Π·ΠΈΡΡ ΠΠ΅ΡΡΡ ΠΠΈΡ Π°ΠΉΠ»ΠΎΠ²ΠΈΡΡ Π§ΡΠΌΠ°ΠΊΠΎΠ²Ρ (Π»Π°Π±. ΠΡΠΎΠ»ΠΈΡΠ΅ΡΠ°ΡΠΈΠΈ ΠΊΠ»Π΅ΡΠΎΠΊ ΠΠ½ΡΡΠΈΡΡΡΠ° ΠΌΠΎΠ»Π΅ΠΊΡΠ»ΡΡΠ½ΠΎΠΉ Π±ΠΈΠΎΠ»ΠΎΠ³ΠΈΠΈ ΠΈΠΌ. Π. Π. ΠΠ½Π³Π΅Π»ΡΠ³Π°ΡΠ΄ΡΠ° Π ΠΠ) Π·Π° ΠΌΠΎΡΠ°Π»ΡΠ½ΡΡ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ ΠΈ ΡΠ΅Π½Π½ΡΠ΅ ΡΠΎΠ²Π΅ΡΡ Π² Ρ ΠΎΠ΄Π΅ ΡΠ°Π±ΠΎΡΡ ΠΈ Π·Π° ΠΏΡΠ΅Π΄ΠΎΡΡΠ°Π²Π»Π΅Π½Π½ΡΠ΅ ΡΠ΅Π°ΠΊΡΠΈΠ²Ρ.
Π‘Π»ΠΎΠ²Π° ΠΎΡΠΎΠ±ΠΎΠΉ ΠΏΡΠΈΠ·Π½Π°ΡΠ΅Π»ΡΠ½ΠΎΡΡΠΈ Ρ ΠΎΡΠ΅Π»Π° Π±Ρ Π²ΡΡΠΊΠ°Π·Π°ΡΡ Π² Π°Π΄ΡΠ΅Ρ ΠΠ½Π½Ρ Π‘Π°Π±Π»ΠΈΠ½ΠΎΠΉ, ΠΊΠΎΡΠΎΡΠ°Ρ Π½Π°ΡΡΠΈΠ»Π° ΠΌΠ΅Π½Ρ ΠΌΠ½ΠΎΠ³ΠΈΠΌ ΠΌΠ΅ΡΠΎΠ΄Π°ΠΌ ΠΈ Π±Π΅Π· ΡΡΠ΅ΠΉ ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΠΈ ΡΡΠ° ΡΠ°Π±ΠΎΡΠ° Π½Π΅ Π±ΡΠ»Π° Π±Ρ Π²ΡΠΏΠΎΠ»Π½Π΅Π½Π° ΡΠ°ΠΊ ΡΠΊΠΎΡΠΎ. Π― Π±Π»Π°Π³ΠΎΠ΄Π°ΡΡ Π ΠΎΠΌΠ°Π½Π° ΠΠΎΠ½Π΄ΡΠ°ΡΠΎΠ²Π° Π·Π° ΠΊΡΠΈΡΠΈΡΠ΅ΡΠΊΠΈΠ΅ Π·Π°ΠΌΠ΅ΡΠ°Π½ΠΈΡ ΠΈ ΡΡΠΈΠΌΡΠ»ΠΈΡΡΡΡΠΈΠ΅ Π΄ΠΈΡΠΊΡΡΡΠΈΠΈ, Π° ΡΠ°ΠΊΠΆΠ΅ ΠΠ»ΡΠ³Ρ Π Π°Π·ΠΎΡΠ΅Π½ΠΎΠ²Ρ ΠΈ ΠΠ»Π΅ΠΊΡΠ°Π½Π΄ΡΠ° ΠΠ°ΡΠΏΠ°ΡΡΡΠ½Π° Π·Π° ΠΏΠΎΠΌΠΎΡΡ Π² ΠΏΠΎΠ΄Π³ΠΎΡΠΎΠ²ΠΊΠ΅ ΠΌΠ°ΡΠ΅ΡΠΈΠ°Π»ΠΎΠ² ΠΊ Π·Π°ΡΠΈΡΠ΅. Π― Π±Π»Π°Π³ΠΎΠ΄Π°ΡΠ½Π° ΡΠ»Π΅Π½Π°ΠΌ Π»Π°Π±ΠΎΡΠ°ΡΠΎΡΠΈΠΉ Π. Π. Π€ΡΠΎΠ»ΠΎΠ²ΠΎΠΉ, Π. Π. Π§ΡΠΌΠ°ΠΊΠΎΠ²Π° ΠΈ Π. Π. ΠΡΠ΄ΠΊΠΎΠ²Π° Π·Π° ΠΏΠΎΠ΄Π΄Π΅ΡΠΆΠΊΡ, Π° ΡΠ°ΠΊΠΆΠ΅ Π²ΡΠ΅ΠΌ, ΠΊΡΠΎ ΠΌΠ½Π΅ ΠΏΠΎΠΌΠΎΠ³Π°Π» Π² Ρ ΠΎΠ΄Π΅ ΡΠ°Π±ΠΎΡΡ.
Π‘ΠΏΠΈΡΠΎΠΊ Π»ΠΈΡΠ΅ΡΠ°ΡΡΡΡ
- Flynn D.C. 2001. Adaptor proteins. Oncogene. 20, 6270−6272.
- Kadrmas J.L., Beckerle M.C. 2004. The LIM domain: from the cytoskeleton to the nucleus. Nat. Rex. Mol. Cell Biol. 5, 920−931.
- Dawid I.B., Breen J.J., Toyama R. 1998. LIM domains: multiple roles as adapters and functional modifiers in protein interactions. Trends Genet. 14,156−162.
- Wang Y., Gilmore T.D. 2001. LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim. Biophys. Acta. 1538,260−272.
- Tanaka Π’., Soriano M.A., Grusby M.J. 2005. SLIM is a nuclear ubiquitin E3 ligase that negatively regulates STAT signaling. Immunity. 22,729−736.
- Ungureanu D., Silvennoinen O. 2005. SLIM trims STATs: Ubiquitin E3 ligases provide insights in the regulation of cytokine signaling. Science’s STKE, 304, pe49.
- Capilli A.D., Schultz D.C., Rauscher III F.J., Borden K.L. 2001. Solution structure of the PHD domain from the KAP-1 corepressor: structural determinants for PHD, RING and LIM zinc-binding domains. EMBOJ. 20,165−177.
- Pawson Π’., Nash P. 2003. Assembly of cell regulatory systems through protein interaction domains. Science. 300,445−452.
- Fanning A.S., Anderson J.M. 1999. PDZ domains: fundamental building blocks in the organization of protein complexes at the plasma membrane. J. Clin. Invest. 103,767−772.
- Pallen M.J., Ponting C.P. 1997. PDZ domains in bacterial proteins. Mol. Microbiol. 26,411 413.
- Ponting C.P. 1997. Evidence for PDZ domains in bacteria, yeast, and plants. Protein Sci. 6, 464−468.
- Harris B.Z., Lim W.A. 2001. Mechanism and role of PDZ domains in signaling complex assembly. J. CellSci. 114, 3219−3231.
- Fan J.-S., Zhang M. 2002. Signaling complex organization by PDZ domain proteins. Neurosignals. 11,315−321.
- Hung A.Y., Sheng M. 2002. PDZ domains: structural modules for protein complex assembly. J. Biol. Chem. 277,5699−5702.
- Besprozvanny I., Maximov A. 2001. Classification of PDZ domains. FEBS Lett. 509, 457 462.
- Songyang Z., Fanning A.S., Fu C., Xu J., Marfatia S.M., Chishti A.H., Crompton A., Chan A.C., Anderson J.M., Cantley L.C. 1997. Recognition of unique carboxyl-terminal motifs by distinct PDZ domains. Science (Washington D.C.) 275, 73−77.
- Van den Berk L.C.J., van Ham M.A., te Lindert M.M., Walma Π’., Aelen J., Vuister G.W., Hendriks W.J.A.J. 2004. The interaction of PTP-BL PDZ domains with RIL: an enigmatic role for the RIL LIM domain. Mol. Biol. Rep. 31, 203−215.
- Ponting C.P., Phillips C., Davies K.E., Blake D.J. 1997. PDZ domains: targeting signaling molecules to sub-membranous sites. Bioessays. 19,469−479.
- Nourry C., Grant S.G.N., Borg J.-P. 2003. PDZ Domain Proteins: Plug and Play! Science’s STKE. re7.
- Jelen F., Oleksy A., Smietana K., Otlewski J. 2003. PDZ domains common players in the cell signaling. Acta Biochim. Pol. 50, 985−1017.
- Yi J., Beckerle M.C. 1998. The human TRIP6 gene encodes a LIM domain protein and maps to chromosome 7q22, a region associated with tumorigenesis. Genomics. 49, 314−316.
- Murthy K.K., Clark K., Fortin Y., Shen S.-H., Banville D. 1999. ZRP-1, a zyxin related protein, interacts with the second PDZ domain of the cytosolic protein tyrosine phosphatase hPTPlE. J. Biol. Chem. 274,20 679−20 687.
- Wang Y., Gilmore T.D. 2001. LIM domain protein Trip6 has a conserved nuclear export signal, nuclear targeting sequences, and multiple transactivation domains. Biochim. Biophys. Acta. 1538,260−272.
- Yi J., Kloeker S., Jensen C.C., Bockholt S., Honda H., Hirai H., Beckerle M.C. 2002. Members of the zyxin family of LIM proteins interact with members of the pl30Cas family of signal transducers. J. Biol. Chem. 277, 9580−9589.
- Sanz-Rodriguez F., Guerrero-Esteo M., Botella L.-M., Banville D, Vary C.P.H., Bernabeu C. 2004. Endoglin regulates cytoskeletal organization through binding to ZRP-1, a member of the LIM family of proteins. J. Biol. Chem. 279, 32 858−32 868.
- Lai Y.-J., Chen C.-S., Lin W.-C., Lin F.-T. 2005. c-Src-mediated phosphorylation of TRIP6 regulates its function in lysophosphatidic acid-induced cell migration. Mol. Cell. Biol. 25, 5859−5868.
- Lee J.W., Choi H.-S., Gyuris J., Brent R., Moore D.D. 1995. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. Endocrinology. 9,243−254.
- Li L., Bin L.H., Liu Y., Chen D., Zhai Z., Shu H.B. 2005. TRIP6 is RIP2-associated common signaling component of multiple NF-ΠΊΠ activation pathways. J. Cell Sci. 118, 555 563.
- Kiess M., Scharm Π., Aguzzi A., Hajnal A., Klemez R., Schwarte-Waldhoff I., Schafer R. 1995. Expression of ril, a novel LIM domain gene, is down-regulated in HRAS-transformed cells and restored inphenotypic revertants. Oncogene. 10, 61−68.
- Cuppen E., Gerrits H., Pepers Π., Wieringa Π., Hendriks W. 1998. PDZ motifs in PTP-BL and RIL bind to internal protein segments in the LIM domain protein RIL. Mol. Biol. Cell. 9, 671−683.
- Xia H., Winokur S.T., Kuo W.L., Altherr M.R., Bredt D.S. 1997. Actinin-associated LIM protein: identification of a domain interaction between PDZ and spectrin-like repeat. J. Cell Biol 139,507−515.
- Wang H., Harrison-Shostak D.C., Lemasters J.J., Herman B. 1995. Cloning of a rat cDNA encoding a novel LIM domain protein with high homology to rat RIL. Gene. 165,267−71.
- Kotaka M., Ngai S.M., Garcia-Barcelo M., Tsui S.K., Fung K.P., Lee C.Y., Waye M.M. 1999. Characterization of the human 36-kDa carboxyl terminal LIM domain protein (hCLIMl). J. CellBiochem. 72,279−285.
- Bashirova A.A., Markelov M.L., Shlykova T.V., Levshenkova E.V., Alibaeva R.A., Frolova E.I. 1998. The human RIL gene: mapping to human chromosome 5q31.1, genomic organization and alternative transcripts. Gene. 210, 239−245.
- Torrado M., Senatorov V.V., Trivedi R., Fariss R.N., Tomarev S.I. 2004. Pdlim2, a novel PDZ-LIM domain protein, interacts with a-actinins and filamin A. Invest. Ophlh. Vis. Sci. 45, 3955−3963.
- Kang S., Xu H., Duan X., Liu J.-J., He Z., Yu F., Zhou S., Meng X.-Q., Cao M., Kennedy G.C. 2000. PCD1, a novel gene containing PDZ and LIM domains, is overexpressed in several human cancers. Cancer Res. 60, 5296−5302.
- Wu R.Y., Gill G.N. 1994. LIM domain recognition of a tyrosine-containing tight turn. J. Biol. Chem. 269,25 085−25 090.
- Boden S.D., Liu Y., Hair G.A., Helms J.A., Hu D., Racine M., Nanes M.S., Titus L. 1998. LMP-1, a LIM-domain protein, mediates BMP-6 effect on bone formation. Endocrinology. 139,5125−5134.
- Kuroda S., Tokunaga C., Kiyohara Y., Higuchi O., Konishi H., Mizuno K., Gill G.N., Kikkawa U. 1996. Protein-protein interaction of zinc finger LIM domains with PKC. J. Biol. Chem. 271,31 029−31 032.
- Zhou Q., Ruiz-Lozano P., Martone M.E., Chen J. 1999. Cypher, a striated muscle-restricted PDZ and LIM domain-containing protein, binds to alpha-actinin-2 and protein kinase C. J. Biol. Chem. 214,19 807−19 813.
- Faulkner G., Pallavicini A., Formentin E., Comelli A., Ievolella C., Trevisan S., Bortoletto G., Scannapieco P., Salamon M., Mouly V., Valle G., Lanfranchi G. 1999. ZASP: a new Z-band alternatively spliced PDZ-motif protein. J. Cell Biol. 146,465−475.
- Passier R., Richardson J.A., Olson E.N. 2000. Oracle, a novel PDZ-LIM domain protein expressed in heart and skeletal muscle. Mech. Develop. 92,277−284.
- Vallenius Π’., Scharm Π., Vesikansa A., Luukko K., Schafer R., Makela T.P. 2004. The PDZ-LIM protein RIL modulated actin stress fiber turnover and enhances the association of alpha-actinin with F-actin. Exp. Cell Res. 293,117−128.
- Andersen O., Ostbye Π’.Π., Gabestad I., Nielsen C., Bardal T. 2004. Molecular characterization of a PDZ-LIM protein in Atlantic salmon (Salmo salar): a fish ortholog of the alpha-actinin-associated LIM-protein (ALP). J. Muscle Res. Cell Motil. 25, 61.
- Szpirer C., Szpirer J., Riviere M., Hagnal A., Kiess M., Scharm Π., Schafer R. 1996. Chromosomal assignment of three rat and human U-rev genes, putative tumor suppressors, down-regulated in malignantly #&4S-transfonned cells. Mamm. Genome. 7, 701−703.
- Venter J.C., Adams M.D., Myers E.W., et al. 2001. The sequence of the human genome. Science. 291,1304−1351.
- Lander E.S., Linton L.M., Birren Π., et al. 2001. Initial sequencing and analysis of the human genome. Nature. 409, 860−921.
- Subramanian G., Adams M.D., Venter J.C., Broder S. 2001. Implications of the human genome for understanding human biology and medicine. J. Am. Med. Assn. 286,2296−2307.
- Modrek Π., Lee Π‘. 2002. A genomic view of alternative splicing. Nat. Genet. 30,13−19.
- Kopelman N.M., Lancet D., Yanai I. 2005. Alternative splicing and gene duplication are inversely correlated evolutionary mechanisms. Nat. Genet. 37,588−589.
- Huang C., Zhou Q., Liang P., Hollander M.S., Sheikh F., Li X., Greaser M., Shelton G.D., Evans S., Chen J. 2003. Characterization and in vivo analysis of splice variants of Cypher. J. Biol. Chem. 278,7360−7365.
- Niederlander N., Fayein N.A., Auffray C., Pomies P. 2004. Characterization of a new human isoform of the enigma homolog family specifically expressed in skeletal muscle. Biochem. Biophys. Res. Co. 325,1304−1311.
- Pomies P., Macalma Π’., Beckerle M.C. 1999. Purification and characterization of an alpha-actinin-binding PDZ-LIM protein that is up-regulated during muscle differentiation. J. Biol. Chem. 274,29 242−29 250.
- Zhou Q., Chu P.-H., Huang C., Cheng C.-F., Martone M.E., Knoll G., Shelton G.D., Evans S., Chen J. 2001. Ablation of Cypher, a PDZ-LIM domain Z-line protein, causes a severe form of congenital myopathy. J. Cell Biol. 155,605−612.
- Lasorella A., Iavarone A. 2006. The protein ENH is a cytoplasmic sequestration factor for Id2 in normal and tumor cells from the nervous system. Proc. Natl. Acad. Sci. USA. 103, 4976−4981.
- Ueki N., Seki N., Yano K., Masuho Y., Saito Π’., Muramatsu M.-a. 1999. Isolation, tissue expression, and chromosomal assignment of a human LIM protein gene, showing homology to rat Enigma homologue (ENH). J. Hum. Genet. 44,256−260.
- Jo K., Rutten Π., Bunn R.C., Bredt D.S. 2001. Actinin-associated LIM protein-deficient mice maintain normal development and structure of skeletal muscle. Mol. Cell. Biol. 21, 1682−1687.
- Altherr M.R., Bengtsson U., Markovich R.P., Winokur S.T. 1995. Efforts toward understanding the molecular basis of fascioscapulohumeral muscular dystrophy. Muscle Nerve. 2, S32-S38.
- Vallenius Π’., Luukko K., Makela T.P. 2000. CLP-36 PDZ-LIM protein associates with nonmuscle alpha-actinin-1 and alpha-actinin-4. J. Biol. Chem. 275,11 100−11 105.
- Kotaka M., Lau Y.-m., Cheung K.-k., Lee S.M.Y., Li H.-y., Chan W.-y., Fung K.-p., Lee C.-y., Waye M.M.Y., Tsui S.K.W. 2001. Elfin is expressed during early heart development. J. Cell. Biochem. 83,463−472.
- Guy P.M., Kenny D.A., Gill G.N. 1999. The PDZ domain of the LIM protein Enigma binds to beta-tropomyosin. Mol. Biol. Cell. 10, 1973−1984.
- Krause A., Zacharias W., Camarata Π’., Linkhart Π., Law E., Lischke A., Miljan E., Simon H.-G. 2004. Tbx5 and Tbx4 transcription factors interact with a new chicken PDZ-LIM protein in limb and heart development. Dev. Biol. 273,106−120.
- Camarata Π’., Bimber Π., Kulisz A., Chew T.-L., Yeung J., Simon H.-G. 2006. LMP4 regulates Tbx5 protein subcellular localization and activity. J. Cell Biol. 174,339−348.
- Vallenius T. 2004. Characterization of actin stress fibers: involvement of PDZ-LIM adapter proteins and the novel Clikl kinase. Academic dissertation.
- Maeno-Hikichi Y., Chang S., Matsumura K., Lai M., Lin H., Nakagawa N., Kuroda S., Π» .
- Zhang J.-f. 2003. A PKCe-ENH-channel complex specifically modulates N-type Ca channels. Nat. Neurosci. 6,468−475.
- Wu R.-y., Durick K., Songyang Z., Cantley L.C., Taylor S.S., Gill G.N. 1996. Specificity of LIM domain interactions with receptor tyrosine kinases. J. Biol. Chem. 271, 15 934−15 941.
- Frey N., Olson E.N. 2002. Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins. J. Biol Chem. 277,13 998−14 004.
- Erdmann K.S. 2003. The protein tyrosine phosphatase PTP-Basophil/Basophil-like: interacting proteins and molecular functions. Eur. J. Biochem. 270,4789−4798.
- Nelson W.J., Nusse R. 2004. Convergence of Wnt, p-catenin, and cadherin pathways. Science. 303, 1483−1487.
- Hermann L., Dittmar Π’., Erdmann K.S. 2003. The protein tyrosine phosphatase PTP-BL associates with the midbody and is involved in the regulation of cytokinesis. Mol. Biol. Cell. 14,230−240.
- Cuppen E., van Ham M., Wansink D.G., de Leeuw A., Wieringa Π., Hendriks W. 2000. The zyxin-related protein TRIP6 interacts with PDZ motifs in the adaptor protein RIL and the protein tyrosine phosphatase PTP-BL. Eur. J. Cell Biol. 79, 283−293.
- Taylor K.A., Taylor D.W., Schachat F. 2000. Isoforms of a-actinin from cardiac, smooth, and skeletal muscle form polar arrays of actin filaments. J. Cell Biol. 149,635−645.
- Honda K., Yamada Π’., Endo R., Ino Y., Gotoh M., Tsuda H., Yamada Y., Chiba H., Hirohashi S. 1998. Actinin-4, a novel actin-bundling protein, associated with cell motility and cancer invasion. J. Cell Biol. 140,1383−1393.
- Broderick M.J.F., Winder S.J. 2005. Spectrin, a-actinin, and dystrophin. Adv. Protein Chem. 70, 203−246.
- Otey C.A., Carpen 0. 2004. a-Actinin revisited: a fresh look at an old player. Cell Motil. Cytoskel. 58,104−111.
- Fu S.-l., Waha A., Vogt P.K. 2000. Identification and characterization of genes upregulated in cells transformed by v-Jun. Oncogene. 19,3537−3545.
- Vanaja D.K., Ballman K.V., Morlan B.W., Cheville J.C., Neumann R.M., Lieber M.M., Tindall D.J., Young C.Y.F. 2006. PDLIM4 repression by hypermethylation as a potential biomarker for prostate cancer. Clin. Cancer Res. 12,1128−1136.
- Welsh J.B., Sapinoso L.M., Su A.I., et al. 2001. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res. 61, 59 745 978.
- Yu Y.P., Landsittel D., Jing L., et al. 2004. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J. Clin. Oncol. 22, 2790−2799.
- Mills J.C., Syder A.J., Hong C.V., Guruge J.L., Raaii F., Gordon J.I. 2001. A molecular profile of the mouse gastric parietal cell with and without exposure to Helicobacter pylori. Proc. Natl. Acad. Sci. USA. 98,13 687−13 692.
- Liu C., Goshu E., Wells A., Fang C.-M. 2003. Identification of the downstream targets of SIM1 and ARNT2, a pair of transcription factors essential for neuroendocrine cell differentiation. J. Biol. Chem. 278,44 857−44 867.
- Gerhardinger Π‘., Costa ΠΠ., Coulombe M.C., Toth I., Hoehn Π’., Grosu P. 2005. Expression of acute-phase response proteins in retinal Miiller cells in diabetes. Invest. Ophth. Vis. Sci. 46,349−357.
- Emi N., Friedmann Π’., Yee J.K. 1991. Pseudotype formation of murine leukemia virus with the G protein of vesicular stomatitis virus. J. Virol. 65,1202−1207.
- Lin S., Gaiano N., Culp P., Burns J.C., Friedmann Π’., Yee J.K., Hopkins N. 1994. Integration and germ-line transmission of a pseudotyped retroviral vector in zebrafish. Science. 265,666−669.
- Coffin J.M., Hughes S.H., Varmus H.E. Retroviruses. 1997. CSHL Press.
- Nguyen Π’.Π., Oberholzer J., Birraux J., Majno P., Morel P., Trono D. 2002. Highly efficient lentiviral vector-mediated transduction of nondividing, fully reimplantable primary hepatocytes. Mol. Ther. 6,199−209.
- Pfeifer A., Ikawa M., Dayn Y., Verma I.M. 2002. Transgenesis by lentiviral vectors: Lack of gene silencing in mammalian embryonic stem cells and preimplantation embryos. Proc. Natl. Acad. Sci. USA. 99,2140−2145.
- Brummelkamp T.R., Bernards R., Agami R. 2002. A system for stable expression of short interfering RNAs in mammalian cells. Science. 296,550−553.
- Barton G.M., Medzhitov R. 2002. Retroviral delivery of small interfering RNA into primary cells. Proc. Natl. Acad. Sci. USA. 99,14 943−14 945.
- Dykxhoom D.M., Novina C.D., Sharp P.A. 2003. Killing the messenger: short RNAs that silence gene expression. Nat. Rev. Mol. Cell Biol. 4,457−467.
- Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. 1998. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature. 391,806−811.
- Ngo H., Tschudi C., Gull K., Ullu E. 1998. Double-stranded RNA induces mRNA degradation in Trypanosoma brucei. Proc. Natl. Acad. Sci. USA. 95,14 687−92.
- Yang S., Tutton S., Pierce E., Yoon K. 2001. Specific double-stranded RNA interference in undifferentiated mouse embryonic stem cells. Mol. Cell. Biol. 21, 7807−16.
- Hutvagner G., McLachlan J., Pasquinelli A.E., Balint Π., Tuschl Π’., Zamore P.D. 2001. A cellular function for the RNA-interference enzyme Dicer in the maturation of the let-7 small temporal RNA. Science. 293, 834−838.
- Moss E.G. 2002. MicroRNAs: hidden in the genome. Current Biology. 12, R138-R140.
- Bartel D.P. 2004. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 116, 281−297.
- Berstein E., Caudy A.A., Hammond S.M. Hannon G.J. 2001. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature. 409, 363−366.
- Caplen N.J., Parrish S., Imani F., Fire A., Morgan R.A. 2001. Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems. Proc. Natl. Acad. Sci. USA. 98, 9742−9747.
- Lee Y., Ahn C., Choi H., Kim J., Yim J., Lee J., Provost P., Radmark O., Kim S., Kim V.N. 2003. The nuclear Rnase III Drosha initiates microRNA processing. Nature. 425,415−419.
- Hammond S.M., Bernstein E., Beach D., Hannon G.J. 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 404,293−296.
- Carmell M.A., Xuan Z., Zhang M.Q., HannonG.J. 2002. The Argonaute family: tentacles that reach into RNAi, developmental control, stem cell maintenance, and tumorigenesis. Genes Dev. 16,2733−2742.
- Sledz C.A., Williams B.R.G. 2005. RNA interference in biology and disease. Blood. 106, 787−794.
- Hammond S.M. 2005. Dicing and slicing: The core machinery of the RNA interference pathway. FEBS Lett. 579, 5822−5829.
- Sui G., Soohoo C., El Bashir A., Gay F., Shi Y., Forrester W.C., Shi Y. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA. 99,5515−5520.
- Paddison P.J., Caudy A.A., Bernstein E., Hannon G.J., Conclin D.S. 2002. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev. 16, 948−958.
- Cullen B.R. 2005. Induction of stable RNA interference in mammalian cells. Gene Ther. 16.
- Inoue H., Nojima H., ΠΠΊΠ°ΡΠ°ΡΠ° Π. 1990. High efficiency transformation of Escherichia coli with plasmids. Gene. 96,23−28.
- Silva J.M., Sachidanandam R., Hannon G.J. 2003. Free energy lights the path toward more effective RNAi. Nat. Genet. 35, 303−305.
- Lukyanov Π.A., Chudakov D.M., Fradkov A.F., Labas Y.A., Matz M.V., Lukyanov S. 2006. Discovery and properties of GFP-like proteins from nonbioluminescent anthozoa. Method. Biochem. Analysis. 47,121−138.
- Chomczynski P. 1992. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Anal. Biochem. 201,134−139.
- Sambrook J., Fritsch E.F., Maniatis Π’., Strategies for cloning in plasmid vectors, in Molecular Cloning, a Laboratory Manual, C. Nolan, Editor. 1989, Cold Spring Harbor Laboratory Press: New York. p. 1.53−51.73.
- Altschul S.F., Madden T.L., Schaffer A.A., Zhang J., Zhang Z., Miller W., Lipman D.J. 1997. Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucl. Acids Res. 25, 3389−3402.
- Small J.V. 1981. Organization of actin in the leading edge of cultured cells: Influence of osmium tetroxide and dehydration on the ultrastructure of actin meshworks. J. Cell Biol. 91, 695−705.
- Cramer L., Mitchison T.J. 1993. Moving and stationary actin filaments are involved in spreading of postmitotic PtK2 cells. J. Cell Biol. 122, 833−843.
- Cramer L.P., Briggs L.J., Dawe H.R. 2002. Use of fluorescently labeled deoxyribonuclease I to spatially measure G-actin levels in migrating and non-migrating cells. Cell Motil. Cytoskeleton. 51,27−38.
- Yee J.K., Miyahora A., LaPorte P., Burns J.C., Friedmann T. 1994. A general method for the generation of high-titer, pantropic retroviral vectors: highly efficient infection of primary hepatocytes. Proc. Natl. Acad. Sci. USA. 91,9564−9568.
- Zeng Y., Wagner E.J., Cullen B.R. 2002. Both natural and designed micro RNAs can inhibit the expression of cognate mRNAs when expressed in human cells. Mol. Cell. 9,1327−1333.
- Lagos-Quintana M., Rauhit R., Lendeckel W., Tuschl T. 2001 Identification of novel genes coding for small expressed RNAs. Science. 294, 853−858.
- Cullen B.R. 2005. RNAi the natural way. Nat. Genets. 37,1163−1165.
- Thiery J.P. 2002. Epithelial-mesenchymal transitions in tumor progression. Nat. Rev. Cancer. 2,442−454.
- Bogenrieder Π’., Herlyn M. 2003 Axis of evil: molecular mechanisms of cancer metastasis. Oncogene. 22, 6524−6536.
- Mareel M., Leroy A. 2003. Clinical, cellular, and molecular aspects of cancer invasion. Physiol. Rev. 83,237−276.
- ΠΠΎΠΏΠ½ΠΈΠ½ Π.Π. 2000. ΠΠΈΡΠ΅Π½ΠΈ Π΄Π΅ΠΉΡΡΠ²ΠΈΡ ΠΎΠ½ΠΊΠΎΠ³Π΅Π½ΠΎΠ² ΠΈ ΠΎΠΏΡΡ ΠΎΠ»Π΅Π²ΡΡ ΡΡΠΏΡΠ΅ΡΡΠΎΡΠΎΠ²: ΠΊΠ»ΡΡ ΠΊ ΠΏΠΎΠ½ΠΈΠΌΠ°Π½ΠΈΡ Π±Π°Π·ΠΎΠ²ΡΡ ΠΌΠ΅Ρ Π°Π½ΠΈΠ·ΠΌΠΎΠ² ΠΊΠ°Π½ΡΠ΅ΡΠΎΠ³Π΅Π½Π΅Π·Π°. ΠΠΈΠΎΡ ΠΈΠΌΠΈΡ. 65, 5−33.
- Bouton A.H., Riggins R.B., Bruce-Staskal P.J. 2001. Functions of the adapter protein Cas: signal convergence and determination of cellular responses. Oncogene. 20, 6448−6458.
- Yun M.-S., Kim S.-E., Jeon S.H., Lee J.-S., Choi K.-Y. 2005. Both ERK and Wnt/(3-catenin pathwys are involved in Wnt3a-induced proliferation. J. Cell Sci. 118, 313−322.
- Lin A.W., Barradas M., Stone J.C., van Aelst L., Serrano M., Lowe S.W. 1998. Premature senescence involving p53 and pl6 is activated in response to constitutive MEK/MAPK mitogenic signaling. Genes Dev. 12,3008−3019.
- Lin A.W., Lowe S.W. 2001. Oncogenic ras activates the ARF-p53 pathway to suppress epithelial cell transformation. Proc. Natl. Acad. Sci. USA. 98, 5025−5030.
- Brenner A.J., Paladugu A., Wang H., Olopade Π. I., Dreyling M.H., Aldaz C.M. 1996. Preferential loss of expression of pl6lSK4a rather than pl94RF in breast cancer. Clin. Cancer Res. 2,1993−1998.
- Foster S.A., Wong D.J., Barrett M.T., Galloway D.A. 1998. Inactivation of pl6 in human mammary epithelial cells by CpG island methylation. Mol. Cell. Biol. 18,1793−1801.
- Bachelder R.E., Yoon S.-O., Franci C., Garcia de Herreros A., Mercurio A.M. 2005. Glycogen synthase kinase-3 is an endogenous inhibitor of Snail transcription- implications for the epithelial-mesenchumal transition. J. Cell Biol. 168,29−33.
- Conacci-Sorell M., Simcha I., Ben-Yedidia Π’., Blechman J., Savagner P., Ben-Ze'ev A. 2003. Autoregulation of E-cadherin expression by cadherin-cadherin interactions: the roles of p-catenin signaling, Slug, and ΠΠΠ Π. J. Cell Biol. 163, 847−857.
- Yang J., Mani S.A., Donaher J.L., Ramaswamy S., Itzykson R., Come C., Savagner P., Gitelman I., Richardson A., Weinberg R.A. 2004. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 117, 927−939.
- Yang J., Mani S.A., Weinberg R.A. 2006. Exploring a new twist on tumor metastasis. Cancer Res. 66,4549−4552.
- Yue J., Mulder K. 2001. Transforming growth factor-p signal transduction in epithelial cells. Pharmacol. Therapeut. 91,1−34.
- Kaminska Π., Wesolowska A., Danilkiewicz M. 2005. TGF beta signalling and its role in tumor pathogenesis. Acta Biochim. Pol. 52,329−337.
- Klaavuniemi Π’., Ylanne J. 2006. Zasp/Cypher internal ZM-motif containing fragments are sufficient to co-locolize with a-actinin Analysis of patient mutations. Exp. Cell Res. 312, 1299−1311.
- Klaavuniemi Π’., Kelloniemi A., Ylanne J. 2004. The ZASP-like motif in actinin-associated LIM protein is required for interaction with the a-actinin rod and for targeting to the muscle Z-line. J. Biol. Chem. 279,26 402−26 410.
- Henderson J.R., Pomies P., Auffray C., Beckerle M.C. 2003. ALP and MLP distribution during myofibrillogenesis in cultured cardiomyocytes. Cell Motil. Cytoskel. 54,254−265.
- Haugland R.P., You W., Paragas V.B., Wells K.S., DuBose D.A. 1994. Simultaneous visualization of G- and F-actin in endothelial cells. J. Histochem. Cytochem. 42, 345−350.
- Pomies P., Pashmforoush M., Vegezzi C., Chien K.R., Auffray C., Beckerle M.C. 2007. The cytoskeleton-associated PDZ-LIM protein, ALP, acts on serum response factor activity to regulate muscle differentiation. Mol. Biol. Cell. 18,1723−1733.
- Spector I., Braet F., Shochet N.R., Bubb M.R. 1999. New anti-actin drugs in the study of the organization of the actin cytoskeleton. Microsc. Res. Techniq. 47,18−37.
- Schoenenberger C.-A., Steinmetz M.O., Stoffler D., Mandilova A., Aebi U. 1999. Structure, assembly, and dynamics of actin filaments in situ and in vitro. Microsc. Res. Techniq. 47, 38−50.
- Taunton J. 2001. Actin filament nucleation by endosomes, lysosomes and secretory vesicles. Curr. Opin. Cell Biol. 13,85−91.
- Spector I., Braet F., Shochet N.R., Bubb M.R. 1999. New anti-actin drugs in the study of the organization and function of the actin cytoskeleton. Microsc. Res. Techniq. 47,18−37.
- Rechsteiner M., Rogers S.W. 1996. PEST sequences and regulation by proteolysis. Trends Biochem. Sci. 21,267−271